Literature DB >> 33925657

Patients with Moyamoya Vasculopathy Evaluated at a Single-Center in The Netherlands; Clinical Presentation and Outcome.

Annick Kronenburg1, Rachel Kleinloog1, Albert van der Zwan1, L Jaap Kappelle1, Luca Regli2, Kees P J Braun1, Catharina J M Klijn1,3.   

Abstract

Information on presentation and outcome of moyamoya vasculopathy (MMV) in European countries is limited. We investigated patient characteristics, treatment and outcome of patients with MMV. We retrieved patient characteristics and treatment information and determined functional outcome (modified Rankin Score (mRS); type of school/work) by structured telephone interviews. We performed uni- and multivariable logistic regression analysis to determine predictors of poor outcome. We included 64 patients with bilateral MMV. In children (31 patients), median age was 5 years (interquartile range (IQR) 2-11) and in adults (33 patients), it was 33 years (IQR 28-41). Predominant mode of presentation was ischemia (children 84%; adults 88%). Modified Rankin Scale (mRS) at presentation was ≤2 in 74%. Revascularization was performed in 42 patients (23 children). Median follow-up time was 46 months (IQR 26-90). During this period, 16 patients had recurrent stroke(s) and four patients died. In 73% of the patients (83% surgical group; 55% medically treated group), mRS was ≤2; 46% were able to return to regular school or work, of whom only 41% were on the same level. Univariable analysis revealed that surgical treatment was associated with lower odds of poor outcome ((mRS ≥ 3), OR 0.24; p = 0.017). This association was no longer statistically significant (OR 3.47; p = 0.067) in the multivariable model, including age and diagnosis (moyamoya disease or moyamoya syndrome). In this cohort of patients with MMV who presented in a single European center, a large proportion had good functional outcome. Nevertheless, less than half were able to attend regular school or were able to work at their previous level, indicating a large impact of the disease on their life.

Entities:  

Keywords:  Western world; adults; children; follow-up; functional outcome; moyamoya; revascularization

Year:  2021        PMID: 33925657     DOI: 10.3390/jcm10091898

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  27 in total

1.  The natural history of moyamoya in a North American adult cohort.

Authors:  Bradley A Gross; Rose Du
Journal:  J Clin Neurosci       Date:  2012-11-10       Impact factor: 1.961

Review 2.  Recent advances in moyamoya disease: pathophysiology and treatment.

Authors:  Annick Kronenburg; Kees P J Braun; Albert van der Zwan; Catharina J M Klijn
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

3.  Effects of different surgical modalities on the clinical outcome of patients with moyamoya disease: a prospective cohort study.

Authors:  Xiaofeng Deng; Faliang Gao; Dong Zhang; Yan Zhang; Rong Wang; Shuo Wang; Yong Cao; Yuanli Zhao; Yuesong Pan; Xun Ye; Xingju Liu; Qian Zhang; Jia Wang; Ziwen Yang; Meng Zhao; Jizong Zhao
Journal:  J Neurosurg       Date:  2017-07-07       Impact factor: 5.115

Review 4.  Revascularisation surgery for paediatric moyamoya: a review of the literature.

Authors:  Lai-Wah Eva Fung; Dominic Thompson; Vijeya Ganesan
Journal:  Childs Nerv Syst       Date:  2005-02-05       Impact factor: 1.475

5.  Moyamoya and extracranial vascular involvement: fibromuscular dysplasia? A report of two children.

Authors:  R R de Vries; P G J Nikkels; J van der Laag; G Broere; K P J Braun
Journal:  Neuropediatrics       Date:  2003-12       Impact factor: 1.947

Review 6.  Moyamoya disease and moyamoya syndrome.

Authors:  R Michael Scott; Edward R Smith
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

7.  Comparison of telephone and face-to-face assessment of the modified Rankin Scale.

Authors:  Paula M Janssen; Nora A Visser; Sanne M Dorhout Mees; Catharina J M Klijn; Ale Algra; Gabriel J E Rinkel
Journal:  Cerebrovasc Dis       Date:  2009-12-01       Impact factor: 2.762

8.  Moyamoya disease in Europeans.

Authors:  Markus Kraemer; Wilhelm Heienbrok; Peter Berlit
Journal:  Stroke       Date:  2008-09-11       Impact factor: 7.914

9.  Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association.

Authors:  Donna M Ferriero; Heather J Fullerton; Timothy J Bernard; Lori Billinghurst; Stephen R Daniels; Michael R DeBaun; Gabrielle deVeber; Rebecca N Ichord; Lori C Jordan; Patricia Massicotte; Jennifer Meldau; E Steve Roach; Edward R Smith
Journal:  Stroke       Date:  2019-03       Impact factor: 7.914

10.  Clinical features of moyamoya disease in the United States.

Authors:  D Chiu; P Shedden; P Bratina; J C Grotta
Journal:  Stroke       Date:  1998-07       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.